Theiler's virus-induced demyelinating disease as an infectious model of progressive multiple sclerosis

Steven C Pike1,2, Nora Welsh1,2, Michael Linzey1,2

  • 1Department of Neurology, Dartmouth Hitchcock Medical Center and Geisel School of Medicine, Lebanon, NH, United States.

Insights

The Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) model offers valuable insights into multiple sclerosis (MS) pathogenesis. This model aids in understanding viral triggers and immune responses relevant to MS.

Area of Science:

  • Neuroimmunology
  • Demyelinating Diseases
  • Viral Pathogenesis

Background:

  • Multiple sclerosis (MS) is a complex neuroinflammatory and neurodegenerative disease with an unknown cause.
  • Infectious agents, such as Human Herpes Viruses (HHV), are hypothesized to play a role in triggering MS.
  • Mechanisms like molecular mimicry, bystander effect, and epitope spreading may initiate central nervous system (CNS) autoimmunity in MS.

Purpose of the Study:

  • To highlight the utility of the Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) model in studying MS.
  • To review the mechanisms of CNS autoimmunity in both MS and TMEV-IDD.
  • To explore the contribution of immune cells to TMEV-IDD immunopathology and its relation to MS.

Main Methods:

  • Review of existing literature on TMEV-IDD and MS.
  • Analysis of immune cell involvement (adaptive, innate, CNS-resident) in TMEV-IDD.
  • Examination of sexual dimorphism in TMEV-IDD and MS.

Main Results:

  • TMEV-IDD shares key mechanisms of CNS autoimmunity with MS.
  • Immune cells play significant roles in TMEV-IDD immunopathology, mirroring MS.
  • Sexual dimorphism is observed in both TMEV-IDD and MS, potentially linked to viral infection responses.

Conclusions:

  • TMEV-IDD is an underutilized murine model that effectively recapitulates critical aspects of MS.
  • This model is crucial for investigating viral hypotheses in MS.
  • TMEV-IDD will be vital for testing future therapeutics targeting MS onset and progression.

Related Concept Videos